Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

132 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Precision medicine and actionable alterations in lung cancer: A single institution experience.
Mambetsariev I, Wang Y, Chen C, Nadaf S, Pharaon R, Fricke J, Amanam I, Amini A, Bild A, Chu P, Erhunmwunsee L, Kim J, Munu J, Pillai R, Raz D, Sampath S, Vora L, Qiu F, Smith L, Batra SK, Massarelli E, Koczywas M, Reckamp K, Salgia R. Mambetsariev I, et al. Among authors: vora l. PLoS One. 2020 Feb 11;15(2):e0228188. doi: 10.1371/journal.pone.0228188. eCollection 2020. PLoS One. 2020. PMID: 32045431 Free PMC article.
An Analysis and Comparison of Survival and Functional Outcomes in Oropharyngeal Squamous Cell Carcinoma Patients Treated with Concurrent Chemoradiation Therapy within City of Hope Cancer Center Sites.
Pharaon R, Chung S, Amini A, Maghami E, Chowdhury A, Vora N, Chang S, Kang R, Gernon T, Hansen K, Kelly C, Ackerman D, Vora L, Sampath S, Massarelli E. Pharaon R, et al. Among authors: vora l, vora n. J Clin Med. 2020 Sep 24;9(10):E3083. doi: 10.3390/jcm9103083. J Clin Med. 2020. PMID: 32987866 Free PMC article.
Vidutolimod in Combination With Atezolizumab With and Without Radiation Therapy in Patients With Programmed Cell Death Protein 1 or Programmed Death-Ligand 1 Blockade-Resistant Advanced NSCLC.
Negrao MV, Papadimitrakopoulou VA, Price AC, Tam AL, Furqan M, Laroia ST, Massarelli E, Pacheco J, Heymach JV, Tsao AS, Walker GV, Vora L, Mauro D, Kelley H, Wooldridge JE, Krieg AM, Niu J. Negrao MV, et al. Among authors: vora l. JTO Clin Res Rep. 2022 Oct 26;4(3):100423. doi: 10.1016/j.jtocrr.2022.100423. eCollection 2023 Mar. JTO Clin Res Rep. 2022. PMID: 36925644 Free PMC article.
Phase I Trial of Ipatasertib Plus Carboplatin, Carboplatin/Paclitaxel, or Capecitabine and Atezolizumab in Metastatic Triple-Negative Breast Cancer.
Yuan Y, Yost SE, Cui Y, Ruel C, Murga M, Tang A, Martinez N, Schmolze D, Waisman J, Patel N, Vora L, Tumyan L, Bozoghlanian M, Stewart D, Frankel PH. Yuan Y, et al. Among authors: vora l. Oncologist. 2023 Jul 5;28(7):e498-e507. doi: 10.1093/oncolo/oyad026. Oncologist. 2023. PMID: 37023705 Free PMC article. Clinical Trial.
To the Editor.
Chen BT, Jain AB, Chu P, Dagis A, Vora L, Maghami E, Salehian B. Chen BT, et al. Among authors: vora l. Endocr Pract. 2015 Feb;21(2):212-3. Endocr Pract. 2015. PMID: 27413791 No abstract available.
132 results